GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CuraScientific Corp (OTCPK:CSTF) » Definitions » COGS-to-Revenue

CuraScientific (CuraScientific) COGS-to-Revenue : 0.52 (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is CuraScientific COGS-to-Revenue?

CuraScientific's Cost of Goods Sold for the three months ended in Sep. 2023 was $0.12 Mil. Its Revenue for the three months ended in Sep. 2023 was $0.23 Mil.

CuraScientific's COGS to Revenue for the three months ended in Sep. 2023 was 0.52.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CuraScientific's Gross Margin % for the three months ended in Sep. 2023 was 47.83%.

CuraScientific COGS-to-Revenue Historical Data

The historical data trend for CuraScientific's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CuraScientific COGS-to-Revenue Chart

CuraScientific Annual Data
Trend Dec20 Dec21 Dec22
COGS-to-Revenue
0.30 0.36 0.35

CuraScientific Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.50 0.52

CuraScientific COGS-to-Revenue Calculation

CuraScientific's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.012 / 0.034
=0.35

CuraScientific's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.12 / 0.23
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CuraScientific  (OTCPK:CSTF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CuraScientific's Gross Margin % for the three months ended in Sep. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.12 / 0.23
=47.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

CuraScientific COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of CuraScientific's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CuraScientific (CuraScientific) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CuraScientific Corp (OTCPK:CSTF) » Definitions » COGS-to-Revenue
Comparable Companies
KAYS ACORQ GCAN SXTC PHBI MJNE CANB NXEN SKYI DMKPQ XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
N/A
Address
51544 Cesar Chavez Street, Suite No. 1J, Coachella, CA, USA, 92236
Website
https://www.curascientificcorp.com
CuraScientific Corp manufactures commercial chemicals with a variety of commercial sterilization applications for agriculture, warehousing, hospitality, and medical facilities. The company's product, DiOx+, is a disinfectant sterilizer that kills harmful pathogens without exposing people or the environment to dangerous toxins.
Executives
Paul Quentin Goyette director 2205 LOCH WAY, EL DORADO HILLS CA 95762
William Joseph Reed director, officer: Chief Executive Officer 333 N UNIVERSITY AVE., #33, REDLANDS CA 92374
Johann Loewen director C/O METHES ENERGIES INTERNATIONAL LTD, 3651 LINDELL ROAD, SUITE D-272, LAS VEGAS NV 89103
Edouard Maurice Beaudette director 13480 N BLOOMFIELD ROAD, NEVADA CITY CA 95959
Justin Michael Gonzalez director, officer: Chief Executive Officer 15723 LAKE VERA PURDON RD., NEVADA CITY CA 95959
Eric Jason Watson director, officer: Chief Operating Officer 19553 BOWERS DRIVE, TOPANGA CA 90290

CuraScientific (CuraScientific) Headlines

From GuruFocus

BOON Industries Announces Initial Purchase Order With Major Beverage Company of 500,000 Units

By Marketwired Marketwired • 05-21-2020

BOON Industries Debuts DiOx+ With $2M in Projected Revenue for Next 12 Months

By Marketwired Marketwired • 05-27-2020

Boon Industries Moves Forward With New Technology & Intellectual Property

By Marketwired Marketwired • 05-19-2020

BOON to Announce Major Contract Start Date for DIOX+ $52M Revenue Stream

By Marketwired Marketwired • 02-03-2021

Introducing Leaf of Faith

By Marketwired Marketwired • 03-26-2019